Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission: The RevascHeart study

医学 射血分数 血运重建 心脏病学 危险系数 内科学 传统PCI 经皮冠状动脉介入治疗 心力衰竭 冠状动脉疾病 置信区间 心肌梗塞
作者
Carlos Moliner‐Abós,Maria Calvo‐Barceló,Eduard Solé‐González,Amandine Martin,Paula Fluvià‐Brugués,Jesús Sánchez‐Vega,Joan Vime‐Jubany,María Ferré Vallverdú,Manel Taurón Ferrer,Pablo Eduardo Tobías-Castillo,Juan Carlos de la Fuente Mancera,Pau Vilardell‐Rigau,Rosa Vila‐Olives,Carles Diez‐López,Antoni Bayés‐Genís,Dabit Arzamendi Aizpurua,Ignacio Ferreira‐González,Sònia Mirabet Pérez
出处
期刊:European Journal of Heart Failure [Elsevier BV]
标识
DOI:10.1002/ejhf.3463
摘要

Abstract Aims Despite numerous trials on revascularization in patients with heart failure (HF) and ischaemic left ventricular (LV) dysfunction, its role remains unsettled. Guideline‐directed medical therapy (GDMT) for HF has shown benefits on outcomes. This multicentre study aims to compare long‐term mortality between revascularization and GDMT in patients with ischaemic LV dysfunction following admission for HF. Methods and results Between 2012 and 2023, 408 patients admitted for HF with a LV ejection fraction (LVEF) of 40% or less and documented coronary artery disease (CAD) were included. Patients were categorized into two groups based on their initial treatment decision: revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) or GDMT. The primary outcome was rate of all‐cause or cardiovascular mortality, and secondary outcomes included type of revascularization (PCI vs. CABG) and LV reverse remodelling. After a median 44.6‐month follow‐up, 100 patients (33%) died in the revascularization group, compared to 44 (43%) in the GDMT group. Multivariate analysis showed no significant benefit of revascularization on all‐cause mortality (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.48–1.39, p = 0.45) or cardiovascular mortality (HR 0.97, 95% CI 0.62–1.52, p = 0.90) compared to GDMT. Neither CABG (HR 0.74, 95% CI 0.51–1.08, p = 0.13) nor PCI (HR 0.98, 95% CI 0.62–1.55, p = 0.93) demonstrated a mortality reduction compared to GDMT. Both groups experienced significant reductions in LV size and improvements in LVEF, greater in the revascularization group. Conclusion Revascularization did not outperform GDMT in ischaemic LV dysfunction following HF admission in this retrospective analysis. Larger prospective studies are needed to clarify the potential role of revascularization in improving outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
丘比特应助洋葱采纳,获得10
1秒前
Fluke完成签到,获得积分10
1秒前
小巧安柏发布了新的文献求助10
2秒前
健忘的芷荷完成签到,获得积分10
3秒前
隐形曼青应助小柯采纳,获得10
3秒前
同尘发布了新的文献求助10
3秒前
傲娇颖发布了新的文献求助10
3秒前
JamesPei应助爱死看文献啦采纳,获得10
4秒前
4秒前
4秒前
4秒前
liu完成签到 ,获得积分10
4秒前
5秒前
量子星尘发布了新的文献求助10
5秒前
5秒前
胡萝卜发布了新的文献求助10
6秒前
西西弗完成签到,获得积分10
6秒前
小吕小吕完成签到,获得积分10
6秒前
Cat完成签到,获得积分0
6秒前
6秒前
隐形大米完成签到,获得积分10
7秒前
若水发布了新的文献求助10
7秒前
慕青应助呃呃诶采纳,获得20
8秒前
同尘完成签到,获得积分20
10秒前
丘比特应助许多年以后采纳,获得10
10秒前
10秒前
西西弗发布了新的文献求助30
11秒前
欣喜代秋发布了新的文献求助10
11秒前
大尾猫完成签到,获得积分10
11秒前
锋洋之恋完成签到,获得积分10
11秒前
11秒前
杜青完成签到,获得积分10
11秒前
12秒前
Mindray完成签到,获得积分10
13秒前
科研通AI5应助天麻zyq采纳,获得30
13秒前
13秒前
洋葱发布了新的文献求助10
14秒前
李健应助又晴采纳,获得10
15秒前
15秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
The First Nuclear Era: The Life and Times of a Technological Fixer 500
ALUMINUM STANDARDS AND DATA 500
Walter Gilbert: Selected Works 500
岡本唐貴自伝的回想画集 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3667657
求助须知:如何正确求助?哪些是违规求助? 3226188
关于积分的说明 9768281
捐赠科研通 2936167
什么是DOI,文献DOI怎么找? 1608152
邀请新用户注册赠送积分活动 759520
科研通“疑难数据库(出版商)”最低求助积分说明 735404